In an interview to CNBC-TV18, SP Tulsian shared his views on the fundamentals of the market.
On pharma stocks, Tulsian said, “Last four to six months, we have been keeping our view restricted on 3-4 pharmaceutical stocks and they are Aurobindo Pharma, Biocon, Divis Lab, and Glenmark."
Today if you see, Biocon is also seen in accumulation, same thing is seen in the case of Aurobindo Pharma also, Tulsian said.
"Divis sometimes show a concentrated move. It does not move in linear fashion or maybe accumulation pattern. It seems to be more of high beta stock. So, we continue to have a positive bias on that. When you have the uncertainty and I have to have the rotation within the sector, you have no choice but to look for Aurobindo Pharma, Divis, and Biocon at this stage," Tulsian added.
On Ashok Leyland, Tulsian said, “I do not think Ashok Leyland numbers seems to be that bad which warrants the correction."
Maybe the sentiments are seen to be little low because overall the auto sales numbers were seen to be bad and, especially for the commercial vehicle (CV) front, he said.
"If you take an isolated call on Ashok Leyland, I do not think the numbers seem to be disappointing looking at the trends. So, maybe I will initiate a buy call on Ashok Leyland at the current levels," Tulsian said.
The views and investment tips expressed by investment experts on CNBCTV18.com are their own and not that of the website or its management. CNBCTV18.com advises users to check with certified experts before taking any investment decisions.